Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Navinta LLC has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 2 art units, so the docket is divided across separate examination assignments.
PALENIK, JEFFREY T is the busiest examiner, with 1 pending matter. The remaining action is assigned elsewhere, making examiner-specific preparation important even though the total docket is small.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18517285 | SOLUTION FORMULATION OF CYCLOPHOSPHAMIDE | AGGARWAL, SAHIL CHANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19042930 | Tablet Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19042930 | Tablet Formulation Of Tafamidis Or Pharmaceutically Acceptable Salt Thereof | PALENIK, JEFFREY T | 1615 | §103 | Non-Final OA | — | Pending | Jan 31, 2025 |
| 18517285 | SOLUTION FORMULATION OF CYCLOPHOSPHAMIDE | AGGARWAL, SAHIL CHANDER | 1623 | §103§112 | Final Rejection | — | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNavinta LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jeffrey T Palenik has the most, with 1 of Navinta LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
